Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Small Cell Lung Cancer and Breast Cancer
Interventions: DRUG: Satoreotide tetraxetan|DRUG: Satoreotide trizoxetan
Sponsor: Ipsen